News

Lonza has submitted a non-binding proposal to acquire all of the outstanding Restricted Voting Shares of Patheon at a price of $3.55 per Restricted Voting Share. Patheon expects

Epocal has received US Food and Drug Administration’s (FDA) clearance to market its new glucose test on the epoc Blood Analysis System. Imants Lauks, president and founder of

Takeda Canada has re-acquired the Canadian commercial rights to ACTOS, an oral treatment for type 2 diabetes, from Eli Lilly Canada. Takeda, the discoverer of ACTOS, licensed the

MediciNova and Avigen have entered into a definitive merger agreement pursuant to which MediciNova’s wholly-owned subsidiary will merge with and into Avigen. Reportedly, completion of the transaction will

Revenue growth on a constant currency basis was 10% after adjusting for a $145 million negative foreign currency translation. This quarter contained 14 weeks, one more week than

The FDA has accepted and filed for review the Cell Therapeutics’ (CTI) New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL).

AspenBio has received a request from the FDA for additional information related to its Premarket Notification 510(k) application for AppyScore test. The application was filed in late June

IntelGenx has reported that the New Drug Application (NDA) filing for the antidepressant – CPI-300 has been accepted by the FDA for standard review. In connection with the

Palio, an inVentiv Health company, has sealed a partnership agreement with Zemoga. The deal is aimed at tackling the changing nature of digital media in the healthcare arena.